Core Findings - Telomir Pharmaceuticals, Inc. announced new preclinical results indicating that its investigational therapy Telomir-1 can restore the body's natural tumor suppressor defenses by reversing abnormal DNA methylation of key genes MASPIN and RASSF1A in aggressive prostate cancer models [1] Group 1: Company Overview - Telomir Pharmaceuticals is a preclinical-stage biotechnology company focused on developing therapies that target epigenetic drivers of cancer, aging, and age-related diseases [1] Group 2: Research Findings - Telomir-1 reactivates two critical tumor suppressor genes, MASPIN and RASSF1A, which are essential for blocking invasion, limiting metastasis, and improving chemotherapy responsiveness in prostate cancer [1]